SCM
ACAD icon

Stonepine Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Stonepine Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$2.39M – 84
2025
Q4 		$2.67M Sell
100,000
-74,544
-43% -$1.78M 2.11% 15
2025
Q3 		$3.72M Sell
174,544
-50,456
-22% -$1.19M 3.03% 8
2025
Q2 		$4.85M Buy
225,000
+131,607
+141% +$2.45M 4.78% 6
2025
Q1 		$186K Sell
93,393
-126,607
-58% -$2.3M 0.18% 51
2024
Q4 		$4.04M Buy
220,000
+23,105
+12% +$373K 3.26% 7
2024
Q3 		$3.03M Buy
196,895
+191,895
+3,838% +$3.2M 1.91% 17
2024
Q2 		$81.3K Buy
+5,000
New +$80.7K 0.07% 25
2018
Q3 		– Sell
-194,900
Closed -$2.98M – 32
2018
Q2 		$2.98M Buy
+194,900
New +$3.48M 1.81% 16

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return